| Literature DB >> 22910842 |
G Cavaletti1, D R Cornblath2, I S J Merkies3, T J Postma4, E Rossi5, B Frigeni6, P Alberti6, J Bruna7, R Velasco7, A A Argyriou8, H P Kalofonos8, D Psimaras9, D Ricard10, A Pace11, E Galiè11, C Briani12, C Dalla Torre12, C G Faber3, R I Lalisang13, W Boogerd14, D Brandsma14, S Koeppen15, J Hense15, D Storey16, S Kerrigan16, A Schenone17, S Fabbri17, M G Valsecchi5, A Mazzeo, A Pace11, A Pessino, A Schenone17, A Toscano, A A Argyriou8, B Brouwer, B Frigeni6, B Piras, C Briani12, C Dalla Torre12, C Dominguez Gonzalez, C G Faber3, C Tomasello, D Binda, D Brandsma14, D Cortinovis, D Psimaras9, D Ricard10, D Storey16, D R Cornblath2, E Galiè11, E Lindeck Pozza, E Rossi5, E K Vanhoutte, F Lanzani, F Pastorelli, G Altavilla, G Cavaletti1, G Granata, H P Kalofonos8, I Ghignotti, I S J Merkies3, J Bruna7, J Hense15, J J Heimans, L Mattavelli, L Padua, L Reni, M Bakkers, M Boogerd, M Campagnolo, M Cazzaniga, M Eurelings, M Leandri, M Lucchetta, M Penas Prado, M Russo, M G Valsecchi5, M L Piatti, P Alberti6, P Bidoli, R Grant, R Plasmati, R Velasco7, R I Lalisang13, R J Meijer, S Fabbri17, S G Dorsey, S Galimberti, S Kerrigan16, S Koeppen15, T J Postma4, W Boogerd14, W Grisold.
Abstract
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. PATIENTS AND METHODS: After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable CIPN were examined. Validity (correlation) and reliability studies were carried out.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22910842 PMCID： PMC3551481 DOI： 10.1093/annonc/mds329
Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976